enGene Holdings Future Growth
Future criteria checks 0/6
enGene Holdings is forecast to grow earnings and revenue by 9.8% and 57.4% per annum respectively. EPS is expected to grow by 93.9% per annum. Return on equity is forecast to be -22.7% in 3 years.
Key information
9.8%
Earnings growth rate
93.9%
EPS growth rate
Biotechs earnings growth | 24.8% |
Revenue growth rate | 57.4% |
Future return on equity | -22.7% |
Analyst coverage | Low |
Last updated | 20 May 2024 |
Recent future growth updates
No updates
Recent updates
Earnings and Revenue Growth Forecasts
Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
---|---|---|---|---|---|
10/31/2026 | 26 | -79 | N/A | N/A | 3 |
10/31/2025 | N/A | -71 | N/A | N/A | 3 |
10/31/2024 | N/A | -54 | N/A | N/A | 3 |
1/31/2024 | N/A | -107 | -27 | -26 | N/A |
10/31/2023 | N/A | -105 | -25 | -25 | N/A |
7/31/2023 | N/A | -31 | -24 | -23 | N/A |
10/31/2022 | N/A | -29 | -18 | -18 | N/A |
10/31/2021 | N/A | -22 | -16 | -16 | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: ENGN is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: ENGN is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: ENGN is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: ENGN is forecast to have no revenue next year.
High Growth Revenue: ENGN is forecast to have no revenue next year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: ENGN is forecast to be unprofitable in 3 years.